EGFR-TKIs在NSCLC中的耐药机制及治疗策略研究进展  

Research progress of the resistance mechanism and reversal strategies of the EGFR-TKIs in NSCLC

作　　者：曾怡馨 王晓 王澍 於曼 甘宗捷[1] ZENG Yixin;WANG Xiao;WANG Shu;YU Man;GAN Zongjie(College of Pharmacy,Chongqing Medical University,Chongqing,400016,China)

机构地区：[1]重庆医科大学药学院,重庆400016

出　　处：《肿瘤药学》2022年第2期161-166,共6页Anti-Tumor Pharmacy

基　　金：重庆医科大学大学生创新创业项目(SRIEP201969)。

摘　　要：表皮生长因子受体(EGFR)抑制剂是目前临床治疗非小细胞肺癌(NSCLC)的一线小分子靶向药物,随着EGFR酪氨酸激酶抑制剂(EGFR-TKI)的广泛使用,其耐药现象也日趋明显,已成为其治疗NSCLC的巨大挑战。本文总结了EGFR-TKIs在NSCLC中的主要耐药机制,并对相关逆转策略的研究进展进行综述。Epidermal growth factor receptor(EGFR)inhibitors are currently the first-line small molecule-targeted drugs commonly used in the treatment of non-small cell lung cancer(NSCLC).However,drug resistance inevitably devel‑oped after long time exposure of the EGFR tyrosine kinase inhibitors(EGFR-TKI),which has become a great challenge in the treatment of NSCLC.In this paper,we summarized the mechanisms of drug resistance of EGFR-TKIs in the treatment of NSCLC and reviewed the research progress of relevant reversal strategies.

关 键 词：非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 耐药 逆转策略 

分 类 号：R734.2[医药卫生—肿瘤] R914[医药卫生—临床医学]